University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.

Passage Bio, a US-based genetic medicines developer exploiting University of Pennsylvania research, raised $216m in an initial public offering yesterday after issuing 12 million shares priced at $18. Passage Bio had hoped to raise $125m when it unveiled plans earlier this month to go public. It subsequently decided to issue 7.4 million shares priced at…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.